ProCE Banner Activity

Adding Long-Acting Injectables to the PrEP Menu

Conference Coverage
Clinical Thought

What lessons can Canadians learn from other countries that have implemented the long-acting injectable PrEP option as we await regulatory approval? I review data from IDWeek and EACS focused on barriers and solutions to improve uptake.

Released: November 14, 2023

Share

Faculty

Darrell H S Tan

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Faculty Disclosure

Primary Author

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Darrell Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead, GlaxoSmithKline.